Format

Send to

Choose Destination
J Atr Fibrillation. 2017 Aug 31;10(2):1575. doi: 10.4022/jafib.1575. eCollection 2017 Aug-Sep.

Is CHA2DS2-VASc Score Different in Patients with Non-valvular Atrial Fibrillation Suffering from Cerebral and Non-cerebral Thromboembolism?CHA2DS2-VASc Score in Thromboembolism.

Author information

1
Afyonkarahisar State Hospital Department of Cardiology Afyonkarahisar/Turkey vemren@hotmail.com.
2
Afyonkarahisar State Hospital Department of Cardiolovascular Surgery Afyonkarahisar/Turkey drfatihada@gmail.com.
3
Afyon Kocatepe University Department of Cardiolovascular Surgery Afyonkarahisar/Turkey draldemir@yahoo.com.
4
Afyon Kocatepe University Department of Cardiolovascular Surgery Afyonkarahisar/Turkey dr_evren_sivas@hotmail.com.
5
Afyon Kocatepe University Department of Cardiolovascular Surgery Afyonkarahisar/Turkey görkemcarsanba@hotmail.com.
6
Afyonkarahisar State Hospital Department of Neurology Afyonkarahisar/Turkey dkiziltancelik@gmail.com.
7
Afyonkarahisar State Hospital Department of Cardiolovascular Surgery Afyonkarahisar/Turkey dr.ersincelik@gmail.com.
8
Afyon Kocatepe University Department of Cardiology Afyonkarahisar/Turkey eonrat@yahoo.com.

Abstract

Background:

Thromboembolic complication is directly related to CHA2DS2-VASc score in patients with non-valvular atrial fibrillation (NVAF). In this study we compared the CHA2DS2-VASc score and in-hospital mortality between NVAF patients with non-cerebral thromboembolism and those with stroke.

Methods:

We retrospectively reviewed medical records of 213 patients with NVAF who experienced stroke and 115 patients with NVAF who experienced non-cerebral thromboembolism between 2010 and 2015. In all patients, CHA2DS2-VASc score before the event was calculated.

Results:

The mean CHA2DS2-VASc score was similar in patients with stroke (4.52±1.66) and those with non-cerebral thromboembolism (4.29±2.02) (p=0.196). In-hospital mortality rate was similar between the groups (19% vs. 17%, p=0.756). The rates of coronary artery disease (52% vs. 38%, p=0.014), prior transient ischemic attack (16% vs. 5%, p=0.001), and prior non-cerebral thromboembolism (18% vs. 3%, p<0.001) were higher in patients with non-cerebral thromboembolism. Warfarin (55% vs. 14% p<0.001) and antiplatelet use (56% vs. 40%, p=0.004) was more common in the non-cerebral embolism group, while non-vitamin K antagonist oral anticoagulant (NOAC) use was more common in the stroke group (15% vs. 7% p=0.026).

Conclusion:

The patients with stroke had similar CHA2DS2-VASc score and in-hospital mortality compared to patients with non-cerebral thromboembolism.

KEYWORDS:

CHA2DS2-VASc score; non-cerebral embolism; non-valvular atrial fibrillation; stroke

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center